LEFT VENTRICULAR ASSIST DEVICES WHERE DOES PALLIATIVE MEDICINE FIT?
|
|
- Joseph George
- 5 years ago
- Views:
Transcription
1 Glennan Center for Geriatrics and Gerontology LEFT VENTRICULAR ASSIST DEVICES WHERE DOES PALLIATIVE MEDICINE FIT? April 7, Marissa Galicia Castillo, MD Medical Director, Sentara Norfolk General Hospital Palliative Care Medicine Palliative Medicine Section MISSION: To integrate, coordinate and disseminate all age related endeavors at the Eastern Virginia Medical School. The Center s ultimate goals are to promote the health, wellbeing, independence, and quality of life of older adults; and to enhance the knowledge base and standards of practice in geriatrics and gerontology, through clinical practice, education, research, and advocacy on behalf of older adults and their caregivers. Glennan Center for Geriatrics and Gerontology Clinical Services Consultation Clinics Geriatric Assessment Memory Assessment Post Acute/Long Term Care Beth Sholom Harbor s Edge Assisted Living Memory Center Palliative Medicine Sentara Norfolk General Hospital Sentara Careplex Sentara Newtown Hospice Hospice and Palliative Care of Tidewater OBJECTIVES Discuss the ethical decisions related to the use of LVAD s in clinical decision making. Explore how palliative care and end of life discussions are relevant to the care of Patients with LVAD s. Share relevant patient care stories to utilize palliative care for this patient population. Describe the process for involving patients in palliative care. 1
2 Facts about Heart failure Reasons we will see more LVADs Mr. O 69 year old LVAD DT Initially did well, POD 5 major stroke ACP would not want to be kept alive by artificial means: specifically named ventilator, dialysis, ACLS did not mention LVAD specifically Palliative Medicine team consulted Family felt LVAD was a part of him did not want it turned off Comfort care with exception of LVAD After 2 months, died on his 70 th birthday Could anything have been done differently? 2
3 Today Mechanical Circulatory Devices Benefits Complications Palliative Medicine topics/topics/vad 3
4 Medicare Indications for Coverage Number of heart transplants 1. Preauthorization 2. Post cardiotomy (acute bridge to recovery) 3. Bridge to transplant 4. Destination Therapy 4
5 Advanced Heart Failure 5.7 million Americans 10 percent have advanced heart failure Conventional heart therapies and symptom management strategies no longer work Shortness of breath and other symptoms even at rest. NYHA Functional Classification for Heart Failure Class Definition I Cardiac Disease. No physical limitation or symptoms with exertion. II Symptom-free at rest. Slight limitation of activity due to fatigue, angina, Dyspnea which resolves with rest. III Symptom-free at rest. Significant limitation of activity due to fatigue, angina, Dyspnea. IV Unable to perform any activity without discomfort. Symptoms of angina, Dyspnea, and fatigue may be present at rest. NYHA, New York Heart Association ACC/AHA Staging System for Heart Failure Stage Definition A High risk for heart failure, no structural defect. Example, diabetes, hypertension B Structural defect causing asymptomatic ventricular dysfunction. Patient has never had clinical heart failure. Example, left ventricular hypertrophy, previous MI C Current or past symptoms of HF associated with structural abnormalities. Most HF patients fit in this group. D Refractory end-stage heart failure. These patients are candidates for heart transplant, specialized interventions or hospice. ACC, American College of Cardiology; AHA, American Heart Association; MI myocardial infarction; HF heart failure 5
6 N Engl J Med 2009;361: Survival Statistics 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Medical Management Destination Therapy Bridge to Transplant 1 year 2 years Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, et al. The Fourth INTERMACS Annual Report: 4,000 implants and counting. J Heart Lung Transplant 2012;31:
7 Complications Mechanical failure Infection Bleeding Strokes Death Before this next slide, write down the first thing you see. 7
8 Preparedness Planning Part of the checklist Focus on completion of Advance Care Planning Definition of Quality of Life Biggest fear Preparedness Planning What ifs Complications When would you feel you would want it turned off? Turning off the LVAD "A Failing Heart And The Downside Of Life Prolonging Technology" Full Essay The device kept him alive, but was the pain and suffering worth it? Health Affairs, August 3,
9 Ms. C 35 yo female s/p LVAD x 6 months after postpartum cardiomyopathy Presents to ED with suicide attempt Cut her driveline What now? Mr. J 70 yo male DT Cognitive impairment after LVAD placement Over next 2 years, progressive cognitive decline Wife having more and more difficulty caring for him Now what? 9
10 GOALS Take Home Points Destination therapy is increasing DT support is a medical intervention that can be withheld or withdrawn when risks/burdens outweigh benefits Treatments Procedures Tests Take Home Points References Preparedness Planning is important Teams are key Communication, communication, communication Fendler TJ, Nassif ME, Kennedy KF, et al. Frequency and assessment of poor global outcome in patients with left ventricular assist devices. Scheduled to be presented at the American Heart Association Quality of Care and Outcomes Research 2015 Scientific Sessions [canceled], April 30, Baltimore, MD, April 30, Available at: Fendler TJ, Spertus JA, Gosch K, et al. Incidence and predictors of cognitive decline in patients with left ventricular assist devices. Scheduled to be presented at the American Heart Association Quality of Care and Outcomes Research 2015 Scientific Sessions [canceled], April 30, Baltimore, MD, April 30, Available at: Ottenberg, AL, Cook KE, Topazian RJ, Mueller LA, Mueller PS, Swetz KM. Choices for Patients Without a Choice, Circ Cardiovasc Qual Outcomes. 2014; 7: Swetz KM, Cook KE, Ottenberg AL, Chang N, Mueller PS. Clinicians attitudes regarding withdrawal of left ventricular assist devices in patients approaching the end of life, European Journal of Heart Failure, 2013; 15: Rady MY, Verheijde JL. Ethical Challenges with Deactivation of Durable Mechanical Circulatory Support at the End of Life: Left Ventricular Assist Devices and Total Artificial Hearts, Journal of ICU, 2015; 29: Swetz KM, Kamal AH, Matlock DD, Dose AM, Borkenhagen LS, Kimeu AK, Dunlay SM, Feely MA. Preparedness Planning Before Mechanical Circulatory Support: A How To Guide for Palliative Medicine Clinicians, 2014; 47(5):
Larry A. Allen, MD, MHS on behalf of the investigators, clinicians, patients, families, and funders. Colorado Program for Patient Centered Decisions
Effectiveness of a Shared Decision Making Intervention for Patients Offered a Destination Therapy Left Ventricular Assist Device for End-Stage Heart Failure: The DECIDE-LVAD Trial Larry A. Allen, MD, MHS
More informationVentricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation
Ventricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation Objectives Current rationale behind use of MCS Patient Selection Earlier?
More informationExploring Options. A decision aid for Left Ventricular Assist Device (LVAD) A device for patients with advanced heart failure
A decision aid for Left Ventricular Assist Device (LVAD) A device for patients with advanced heart failure Exploring Options You are being considered for an LVAD. This booklet is designed to help you understand
More informationIs it time to consider a HEARTMATE LEFT VENTRICULAR ASSIST DEVICE (LVAD)?
Is it time to consider a HEARTMATE LEFT VENTRICULAR ASSIST DEVICE (LVAD)? A treatment for advanced heart failure. LAURA HeartMate II LVAD Recipient What is HEART FAILURE? Heart failure sometimes called
More informationThe Interface of Cardiology and Palliative Medicine
The Interface of Cardiology and Palliative Medicine Nathan Goldstein, MD Associate Professor Hertzberg Palliative Care Institute Brookdale Department of Geriatrics and Palliative Medicine Mount Sinai School
More informationLIVING A MORE ACTIVE LIFE. with the HeartMate 3 LVAD for the treatment of advanced heart failure RON. Recipient
LIVING A MORE ACTIVE LIFE with the HeartMate 3 LVAD for the treatment of advanced heart failure RON HeartMate 3 LVAD Recipient What is HEART FAILURE? Heart failure sometimes called a weak heart occurs
More informationAcute Circulatory Support Should We or Shouldn t We?
Acute Circulatory Support Should We or Shouldn t We? Navin K. Kapur, MD, FACC, FSCAI Assistant Professor, Division of Cardiology Director, Acute Circulatory Support Program Director, Interventional Research
More informationExploring Options. A decision aid for Left Ventricular Assist Device (LVAD) A device for patients with advanced heart failure
A decision aid for Left Ventricular Assist Device (LVAD) A device for patients with advanced heart failure Exploring Options You are being considered for an LVAD. This booklet is designed to help you understand
More informationExploring Options. A decision aid for Left Ventricular Assist Device (LVAD) as Destination Therapy A device for patients with advanced heart failure
A decision aid for Left Ventricular Assist Device (LVAD) as Destination Therapy A device for patients with advanced heart failure Exploring Options You are being considered for an LVAD. This booklet is
More informationOriginally indicated as a bridge to transplantation, left
ETHICS, PUBLIC POLICY AND MEDICAL ECONOMICS A Call for Guidance in the Use of Left Ventricular Assist Devices in Older Adults Caroline A. Vitale, MD, * Rashmi Chandekar, MD, Phillip E. Rodgers, MD, Francis
More informationHEARTMATE II LEFT VENTRICULAR ASSIST SYSTEM. HeartMate II Left Ventricular Assist Device
HEARTMATE II LEFT VENTRICULAR ASSIST SYSTEM HeartMate II Left Ventricular Assist Device HeartMate II Left Ventricular Assist Device UNPARALLELED REAL-WORLD EXPERIENCE Over 25,000 heart failure patients
More informationLeft Ventricular Assist Devices (LVADs): Overview and Future Directions
Left Ventricular Assist Devices (LVADs): Overview and Future Directions FATIMA KARAKI, M.D. PGY-3, DEPARTMENT OF MEDICINE WASHINGTON UNIVERSITY IN ST. LOUIS ST. LOUIS, MISSOURI, USA St. Louis, Missouri,
More informationVentricular Assist Devices for Permanent Therapy: Current Status and Future
Ventricular Assist Devices for Permanent Therapy: Current Status and Future Prospects Francis D. Pagani MD PhD Professor of Cardiac Surgery University of Michigan April 28 th, 2012 Disclosures NHLBI and
More informationAdvances in Advanced Heart Failure Therapies. Disclosures. Management Algorithm for Patients in Cardiogenic Shock
Advances in Advanced Heart Failure Therapies 9 th Annual Dartmouth Conference on Advances in Heart Failure Therapies Dartmouth-Hitchcock Medical Center May 20, 2013 Joseph G. Rogers, M.D. Associate Professor
More informationFifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients
http://www.jhltonline.org SPECIAL FEATURE Fifth INTERMACS annual report: Risk factor analysis from more than 6, mechanical circulatory support patients James K. Kirklin, MD, a David C. Naftel, PhD, a Robert
More informationMechanical Circulatory Support in the Management of Heart Failure
Mechanical Circulatory Support in the Management of Heart Failure Feras Bader, MD, MS, FACC Associate Professor of Medicine Director, Heart Failure and Transplant Cleveland Clinic Abu Dhabi Chairman, Heart
More informationWhen to implant VAD in patients with heart transplantation indication. Aldo Cannata Dept of Cardiac Surgery Niguarda Ca Granda Hospital Milano
When to implant VAD in patients with heart transplantation indication Aldo Cannata Dept of Cardiac Surgery Niguarda Ca Granda Hospital Milano LVAD strategies In waiting list? Goal Bridge to transplant
More informationDerivation and Validation of a Novel Right-Sided Heart Failure Model After Implantation of Continuous Flow Left Ventricular Assist Devices: the EUROMACS-RHF Risk Score Osama I.I. Soliman, MD, PhD, FACC,
More informationThe Next Generation of Advance Directives. Carol Wilson, MSHA Director of Palliative Care and Advance Care Planning Riverside Health System
The Next Generation of Advance Directives Carol Wilson, MSHA Director of Palliative Care and Advance Care Planning Riverside Health System Need for a Better System Only 25% of all adults have Advance Directives
More informationHeart 101. Objectives. Types of Heart Failure How common is HF? Sign/Symptoms, when to see a doctor? Diagnostic testing
EXAMING HEART FAILURE: HOW TO RECOGNIZE AND TREAT THE WEAK HEART What is Heart Failure? Treatment of Heart Failure End Stage Heart Failure Munir S. Janmohamed M.D. FACC Assistant Clinical Professor of
More informationLVADs as Destination Therapy: When Best Practice Criteria Meets the Real World
LVADs as Destination Therapy: When Best Practice Criteria Meets the Real World Farooq Sheikh, M.D., FACC Advanced Heart Failure Program MedStar Washington Hospital Center Disclosure I have no relevant
More informationVents, LVADs, and Hospice Oh My!
Vents, LVADs, and Hospice Oh My! Colleen Gilmore RN, MSN, ANP-BC Patrick White MD, HMDC, FACP, FAAHPM 1 Disclosure: White, Patrick, M.D. Patrick White M.D. has financial interests to disclose. Potential
More informationWhat has INTERMACS Taught Us about Patient Outcomes with Durable MCS? James K. Kirklin, MD
What has INTERMACS Taught Us about Patient Outcomes with Durable MCS? James K. Kirklin, MD Disclosure: I am Director of the Data Coordinating Center for the INTERMACS project and receive support through
More informationHFA- ESC criteria for Advanced HF and US Requirements for Destination Therapy
HFA- ESC criteria for Advanced HF and US Requirements for Destination Therapy ESC- HFA criteria for Adv-HF Severe symptoms of HF (NYHA class III or IV) with episodes of fluid retention and/or peripheral
More informationNovel Devices for End-Stage Heart Failure
Novel Devices for End-Stage Heart Failure Lynne Warner Stevenson No conflicts of interest Off-label assist devices and expanded indications will be discussed Devices for End-Stage Heart Failure New definitions
More informationEstablishing a Successful Inotropic Therapy Sales Program
Establishing a Successful Inotropic Therapy Sales Program Jan Ruel Juneau, RN, CRNI, Regional Sales Manager and Bill Miller, RPh, Branch Manager, CarePoint Partners, Metairie, LA Top 4 Things to Know for
More informationGiving your heart strength. Ventricular Assist Device.
Giving your heart strength. Ventricular Assist Device. 1 National leader in Ventricular Assist Devices Although you may be nervous when considering heart surgery, you can rest assured knowing that UR Medicine
More informationEnd of life care for people with heart failure: Where are we now?
End of life care for people with heart failure: Where are we now? Dr James Beattie Consultant Cardiologist, Heart of England NHS Foundation Trust, Birmingham Trustee & Chair, Heart Failure Group, National
More informationRamani GV et al. Mayo Clin Proc 2010;85:180-95
THERAPIES FOR ADVANCED HEART FAILURE: WHEN TO REFER Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac Transplantation
More informationเอกราช อร ยะช ยพาณ ชย
30 July 2016 เอกราช อร ยะช ยพาณ ชย Heart Failure and Transplant Cardiology aekarach.a@chula.ac.th Disclosure Speaker, CME service: Merck, Otsuka, Servier Consultant, non-cme service: Novartis, Menarini
More informationThe Role of Palliative Care in the Management of Advanced Heart Failure
Disclosure The Role of Palliative Care in the Management of Advanced Heart Failure I have no conflict of interest to disclose. Darrell Craig MD Medical Director, Palliative Care Services St. Joseph Mercy
More informationPredicting Major Outcomes after MCSD Implant. Risk Factors for Death, Transplant, and Recovery. James Kirklin, MD David Naftel, PhD
Predicting Major Outcomes after MCSD Implant Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD 1 I have no financial disclosures (I am the Principle Investigator for
More informationSeventh INTERMACS annual report: 15,000 patients and counting
http://www.jhltonline.org INTERMACS ANNUAL REPORT Seventh INTERMACS annual report: 15,000 patients and counting James K. Kirklin, MD, a David C. Naftel, PhD, a Francis D. Pagani, MD, PhD, b Robert L. Kormos,
More informationAbby Woods, DNP, FNP Southern Illinois Healthcare Supportive Care Program END OF LIFE ISSUES IN THE CARE OF CARDIAC PATIENTS
Abby Woods, DNP, FNP Southern Illinois Healthcare Supportive Care Program END OF LIFE ISSUES IN THE CARE OF CARDIAC PATIENTS Objectives Describe a team approach in the setting of critical illness Differentiate
More informationWHEN TO REFER FOR ADVANCED HEART FAILURE THERAPIES
WHEN TO REFER FOR ADVANCED HEART FAILURE THERAPIES Mrudula R Munagala, M.D., FACC CO- Director Heart Failure & Circulatory Support Program OklahomaHeart.com Heart Failure Prevalence Heart Failure affects
More informationIs a LVAD the Right Treatment for Me? Decision Aid
Is a LVAD the Right Treatment for Me? Decision Aid patienteducation.osumc.edu 2 Making an Informed Decision Review this book We give you this information to help you understand what the LVAD treatment
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationHEARTMATE 3 LEFT VENTRICULAR ASSIST SYSTEM
HEARTMATE 3 LEFT VENTRICULAR ASSIST SYSTEM A New Milestone in LVAD Therapy HeartMate 3 Left Ventricular Assist Device Introducing the new HEARTMATE 3 LVAD WITH FULL MAGLEV FLOW TECHNOLOGY HeartMate 3 LVAD
More informationORIGINAL ARTICLE. Alexander M. Bernhardt a, *, Theo M.M.H. De By b, Hermann Reichenspurner a and Tobias Deuse a. Abstract INTRODUCTION
European Journal of Cardio-Thoracic Surgery 48 (2015) 158 162 doi:10.1093/ejcts/ezu406 Advance Access publication 29 October 2014 ORIGINAL ARTICLE Cite this article as: Bernhardt AM, De By TMMH, Reichenspurner
More informationHow do Readmissions Impact Survival among Patients with Continuous-Flow Left Ventricular Assist Devices? Findings from INTERMACS
How do Readmissions Impact Survival among Patients with Continuous-Flow Left Ventricular Assist Devices? Findings from INTERMACS Rey P. Vivo, MD 1 ; Selim R. Krim, MD 2 ; Jerry D. Estep, MD 3 ; Wissam
More informationConcomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis
Concomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis April 11, 2014 Jason O. Robertson, M.D., M.S.; David C. Naftel, Ph.D., Sunil
More informationImplantable Ventricular Assist Devices and Total Artificial Hearts. Policy Specific Section: June 13, 1997 March 29, 2013
Medical Policy Implantable Ventricular Assist Devices and Total Artificial Hearts Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective
More informationAndrew Civitello MD, FACC
Timing the Transition from Short Term to Long Term Mechanical Circulatory Support Andrew Civitello MD, FACC Medical Director, Heart Transplant Program Director, Fellowship Co-Director, Baylor St. Luke's
More informationPredicting Outcomes in LVAD Recipients
Predicting Outcomes in LVAD Recipients Sean P. Pinney, MD Director, Advanced Heart Failure & Cardiac Transplantation Professor of Medicine, Cardiology Icahn School of Medicine at Mount Sinai New York,
More informationAdvanced Care for Decompensated Heart Failure
Advanced Care for Decompensated Heart Failure Sara Kalantari MD Assistant Professor of Medicine, University of Chicago Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation
More informationPalliative Care Consultation and LVAD selection, the Social Work Role.
Palliative Care Consultation and LVAD selection, the Social Work Role. Hospice and Palliative Care Association of New York March 2017 Stuart Kaufer, LMSW, Maimonides Medical Center Save the Date www.rentlikeapro.com
More informationCARDIOMEMS HF SYSTEM HOW TO STAY ABOVE HEART FAILURE: TALKING TO YOUR PATIENT ABOUT THE
CARDIOMEMS HF SYSTEM HOW TO STAY ABOVE HEART FAILURE: TALKING TO YOUR PATIENT ABOUT THE CARDIOMEMS HF SYSTEM This overview of clinical workflow best practices and patient talking points is based on in-depth
More informationWhat Is Best Care for Patients with End stage heart failure?
What Is Best Care for Patients with End stage heart failure? Jin Joo Park, MD Cardiovascular Center, Department of Internal Medicine Bundang Hospital NYHA Class Class Patient Symptoms I No limitation of
More informationHEARTMATE 3 LVAD WITH FULL MAGLEV FLOW TECHNOLOGY THEIR FUTURE STARTS WITH YOU
HEARTMATE 3 WITH FULL MAGLEV FLOW TECHNOLOGY THEIR FUTURE STARTS WITH YOU HEARTMATE 3 with Full MagLev Flow Technology HEARTMATE 3 DELIVERS UNPRECEDENTED * SURVIVAL AND SAFETY OUTCOMES **1 LANDMARK SURVIVAL
More informationDevice Therapy for Heart Failure
Device Therapy for Heart Failure Dr. Shelley Zieroth FRCPC Assistant Professor, Cardiology, University of Manitoba Director of Cardiac Transplant and Heart Failure Clinics St Boniface General Hospital,
More informationCase - Advanced HF and Shock (INTERMACS 1)
Case - Advanced HF and Shock (INTERMACS 1) Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional Cardiology & Advanced Heart Failure Programs Executive Director,
More informationMEDICAL POLICY SUBJECT: VENTRICULAR ASSIST DEVICES
MEDICAL POLICY PAGE: 1 OF: 7 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationAdvanced Heart Failure: Palliative Care and Hospice. Objectives. Models of Care. Susan Glod, MD
Advanced Heart Failure: Palliative Care and Hospice Susan Glod, MD Objectives Redefining Palliative Medicine How can we help? Identifying barriers What next? Models of Care Goal: Prolong life Goal: Prolong
More informationLessons learned from ENDURANCE, ROADMAP, MedaMACS, and how to go forward?
Lessons learned from ENDURANCE, ROADMAP, MedaMACS, and how to go forward? Mark S. Slaughter, MD Professor and Chair Department of Cardiovascular and Thoracic Surgery University of Louisville What could
More informationPatient Details Hidden. Clinical Enrollment. Quality of Life. EuroQOL (EQ-5D) Enroll Patient. Not Started. Not Started
Patient Details Hidden Show Patient Clinical Enrollment t Started Quality of Life t Started EuroQOL (EQ-5D) Did the patient complete a EuroQOL form? Please select a reason why the EuroQOL was not completed:
More informationMedStar Health considers External Counterpulsation Therapy (ECP) medically necessary for the following indications:
MedStar Health, Inc. POLICY AND PROCEDURE MANUAL MP.107.MH External Counterpulsation Therapy This policy applies to the following lines of business: MedStar Employee (Select) MedStar MA DSNP CSNP MedStar
More informationAdvanced Heart Failure: The Nuts & Bolts of Therapies Beyond Medications
Advanced Heart Failure: The Nuts & Bolts of Therapies Beyond Medications Sanjeev K. Gulati MD FACC Director, Heart Failure Sanger Heart and Vascular Institute Carolinas Medical Center Charlotte NC Sanjeev.Gulati@carolinashealthcare.org
More informationStrengthening Your VAD Program
Disclosure: I have no financial conflicts of interest. Strengthening Your VAD Program Octavio E. Pajaro MD, PhD Chair, Cardiothoracic Surgery Mayo Clinic Arizona Surgical Director, Heart Transplantation
More informationAdvanced Heart Failure: Patient Identification and Treatment Options. Donald Haas, MD, MPH Abington - Jefferson Health Abington, PA
Advanced Heart Failure: Patient Identification and Treatment Options Donald Haas, MD, MPH Abington - Jefferson Health Abington, PA Disclosures I have received honoraria from Thoratec Corporation/St. Jude
More informationRecent Trials With Durable LVADs: Is There a Superior Device?
Recent Trials With Durable LVADs: Is There a Superior Device? Francis D. Pagani MD PhD Otto Gago MD Endowed Professor of Cardiac Surgery Michigan Medicine Current Device Landscape 2018 HeartMate 3 HeartMate
More informationStage D Heart Failure. Eric Adler MD Associate Clinical Professor of Medicine Medical Director Cardiac Transplantation
Stage D Heart Failure Eric Adler MD Associate Clinical Professor of Medicine Medical Director Cardiac Transplantation What are the Stages of HF Stage Description Treatment A At risk for HF B Structural
More informationMechanical assist patient selection, device selection, and outcomes
Mechanical assist patient selection, device selection, and outcomes Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine
More informationMulticenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes
Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with (MOMENTUM 3) Long Term Outcomes Mandeep R. Mehra, MD, Daniel J. Goldstein, MD, Nir Uriel, MD, Joseph
More informationSixth INTERMACS annual report: A 10,000-patient database
http://www.jhltonline.org INTERMACS ANNUAL FEATURE Sixth INTERMACS annu report: A 10,000-patient database James K. Kirklin, MD, a David C. Naftel, PhD, a Francis D. Pagani, MD, PhD, b Robert L. Kormos,
More informationKnowing your treatment options can give you hope for a longer, better life
Heart failure is a deadly disease Knowing your treatment options can give you hope for a longer, better life With heart failure, it was not a matter of if I would get worse; it was a matter of when, and
More informationEnd of Life Care in IJN Our journey. Dato Dr. David Chew Soon Ping Consultant Cardiologist National Heart Institute Malaysia
End of Life Care in IJN Our journey Dato Dr. David Chew Soon Ping Consultant Cardiologist National Heart Institute Malaysia End of Life Dying is final part of everyone journey in life Deaths used to occur
More informationRisk Stratification in Heart Failure: The Role of Emerging Biomarkers
Risk Stratification in Heart Failure: The Role of Emerging Biomarkers David G. Grenache, PhD Associate Professor of Pathology, University of Utah Medical Director, ARUP Laboratories Salt Lake City, UT
More informationBackground: Left Ventricular Assist Device (LVAD) patients have shown improvements in
Abstract Background: Left Ventricular Assist Device (LVAD) patients have shown improvements in measures of quality of life and functional status compared to those who are medically managed. Qualitative
More informationMechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know!
Mechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know! Matthew A. Wanat, PharmD, BCPS, BCCCP, FCCM Clinical Assistant Professor University of Houston College of Pharmacy Clinical Pharmacy
More informationDestination Therapy SO MUCH DATA IN SUCH A SMALL DEVICE. HeartWare HVAD System The ONLY intrapericardial VAD approved for DT.
DT Destination Therapy SO MUCH DATA IN SUCH A SMALL DEVICE. HeartWare HVAD System The ONLY intrapericardial VAD approved for DT. ONLY WE HAVE THIS BREADTH OF CLINICAL EVIDENCE TO SUPPORT DESTINATION THERAPY.
More informationTrends in left ventricular assist device use and outcomes among Medicare
To cite: Lampropulos JF, Kim N, Wang Y, et al. Trends in left ventricular assist device use and outcomes among Medicare beneficiaries, 2004 2011. Open Heart 2014;1:e000109. doi:10.1136/openhrt-2014-000109
More informationWithholding & Withdrawing Life Sustaining Treatment: A Lifespan Approach
Withholding & Withdrawing Life Sustaining Treatment: A Lifespan Approach Kenneth Brummel-Smith, M.D. Charlotte Edwards Maguire Professor, Department of Geriatrics FSU College of Medicine Basic Concepts
More informationThe Centers for Medicare & Medicaid Services (CMS) proposes the following changes to the current national coverage determination (NCD).
Proposed Decision Memo for Ventricular Assist Devices for Bridge-to-Transplant and Destination Therapy (CAG-00432R) Decision Summary The Centers for Medicare & Medicaid Services (CMS) proposes the following
More informationAdvancing Cardiovascular Care of the Oncology Patient
Advancing Cardiovascular Care of the Oncology Patient Why Are We Here? The Intersection Between Cardiology and Oncology Feb 17, 2017 Mary Norine Walsh, MD, FACC Medical Director, HF and Cardiac Transplantation
More informationLEFT VENTRICULAR ASSIST DEVICE COMPLICATIONS. Daniel Vargas, MD Section of Cardiothoracic Imaging University of Colorado Anschutz Medical Campus
LEFT VENTRICULAR ASSIST DEVICE COMPLICATIONS Daniel Vargas, MD Section of Cardiothoracic Imaging University of Colorado Anschutz Medical Campus OBJECTIVES Review the most common LVAD-related complications.
More information12/6/2016. Objective PALLIATIVE CARE IN THE NURSING HOME. Medical Care in the US. Palliative Care
Objective PALLIATIVE CARE IN THE NURSING HOME Deborah Morris, M.D., M.H.S. Assistant Professor of Medicine The Glennan Center for Geriatrics and Gerontology Eastern Virginia Medical School Describe program
More informationMechanical Cardiac Support in Acute Heart Failure. Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research
Mechanical Cardiac Support in Acute Heart Failure Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research Disclosures Research Support and/or Consulting NHLBI Amgen Cytokinetics
More informationStatus of Implantable VADs
Status of Implantable VADs John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine Division of Cardiac Surgery The Johns Hopkins Medical Institutions Conflict of Interest Statement
More informationTed Feldman, M.D., MSCAI FACC FESC
Support Technologies and High Risk Intervention Patient Selection: When Not to Use Them Ted Feldman, M.D., MSCAI FACC FESC Evanston Hospital SCAI Fall Fellows Course Las Vegas December 7-10 th, 2014 Ted
More informationBETTER HEART FAILURE MANAGEMENT FROM THE COMFORT OF YOUR HOME
BETTER HEART FAILURE MANAGEMENT FROM THE COMFORT OF YOUR HOME Staying Ahead of Heart Failure with the CardioMEMS HF System The CardioMEMS HF System A UNIQUE APPROACH TO HEART FAILURE MANAGEMENT THAT CAN
More informationManagement Strategies for Advanced Heart Failure
Management Strategies for Advanced Heart Failure Mary Norine Walsh, MD, FACC Medical Director, HF and Cardiac Transplantation St Vincent Heart Indianapolis, IN USA President American College of Cardiology
More informationOverview of MCS in Bruce B Reid, MD Surgical Director Artificial Heart Program/Heart Transplantation
Overview of MCS in 2017 Bruce B Reid, MD Surgical Director Artificial Heart Program/Heart Transplantation Technology Embracing Progress Technology Adoption Internet Adoption of Technology Pioneer in the
More informationMEDICAL POLICY No R8 VENTRICULAR ASSIST DEVICES & ARTIFICIAL HEARTS
VENTRICULAR ASSIST DEVICES & ARTIFICIAL HEARTS Effective Date: January 29, 2018 Review Dates: 8/05, 6/06, 6/07, 6/08, 10/08, 10/09, 10/10, 10/11, 10/12, 10/13, 11/14, 11/15, 11/16, 11/17, 11/18 Date Of
More informationDEMYSTIFYING VADs. Nicolle Choquette RN MN Athabasca University
DEMYSTIFYING VADs Nicolle Choquette RN MN Athabasca University Objectives odefine o Heart Failure o VAD o o o o Post Operative Complications Acute Long Term Nursing Interventions What is Heart Failure?
More informationA Fully Magnetically Levitated Left Ventricular Assist Device. Final Report of the MOMENTUM 3 Trial
A Fully Magnetically Levitated Left Ventricular Assist Device Final Report of the MOMENTUM 3 Trial Mandeep R. Mehra, MD, Nir Uriel, MD, Joseph C. Cleveland, Jr., MD, Daniel J. Goldstein, MD, National Principal
More information864 Stewart et al. The Journal of Heart and Lung Transplantation September 2009 ventricular ejection fraction (LVEF) 35% and symptomatic heart failure
FEATURED ARTICLES Thresholds of Physical Activity and Life Expectancy for Patients Considering Destination Ventricular Assist Devices Garrick C. Stewart, MD, a Kimberly Brooks, RN, a Parakash P. Pratibhu,
More informationLVAD Complications, Recovery
LVAD Complications, Recovery Abbas Ardehali, M.D., F.A.C.S. Professor of Surgery and Medicine, Division of Cardiac Surgery William E. Connor Chair in Cardiothoracic Transplantation Director, UCLA Heart,
More informationMEDICAL POLICY No R8 VENTRICULAR ASSIST DEVICES & ARTIFICIAL HEARTS
VENTRICULAR ASSIST DEVICES & ARTIFICIAL HEARTS Effective Date: January 29, 2018 Review Dates: 8/05, 6/06, 6/07, 6/08, 10/08, 10/09, 10/10, 10/11, 10/12, 10/13, 11/14, 11/15, 11/16, 11/17 Date Of Origin:
More informationMEDICAL POLICY SUBJECT: VENTRICULAR ASSIST DEVICES. POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: VENTRICULAR ASSIST DEVICES PAGE: 1 OF: 8 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including
More informationWHAT S NEW IN HEART FAILURE
WHAT S NEW IN HEART FAILURE Drugs, Devices and Diagnostics John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine Eastern Virginia Medical School
More informationHow to overcome barriers to Palliative Care provision for patients with heart failure. Dr. Piotr Sobanski Prof. Dr.
How to overcome barriers to Palliative Care provision for patients with heart failure Dr. Piotr Sobanski Prof. Dr. Bernd Alt-Epping 1 When have you experienced barriers in providing Palliative Care for
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationFacts. STRONG Risk Factors for HF* LVAD, BiVAD, RVAD, HVAD 10/21/ million adults in the US have heart failure.
10/21/18 1 Facts 5.8 million adults in the US have heart failure. About ½ of those who have HF have a 5 year life expectancy. STRONG Risk Factors for HF* Coronary Heart Disease/MI/Afib COPD Renal Failure
More informationVAD come Destination therapy nell adulto con Scompenso Cardiaco
VAD come Destination therapy nell adulto con Scompenso Cardiaco Francesco Santini Division of Cardiac Surgery, IRCCS San Martino IST University of Genova Medical School, Italy Heart Transplantation is
More informationCHANGING THE WAY HEART FAILURE IS TREATED. VAD Therapy
CHANGING THE WAY HEART FAILURE IS TREATED VAD Therapy VAD THERAPY IS BECOMING AN ESSENTIAL PART OF HEART FAILURE PROGRAMS AROUND THE WORLD. Patients with advanced heart failure experience an impaired quality
More informationEMS and Nursing Considerations in VAD Patient Care
EMS and Nursing Considerations in VAD Patient Care B R I T T A N Y B U T Z L E R B S N R N V A D C O O R D I N A T O R F R O E D T E R T A N D T H E M E D I C A L C O L L E G E O F W I 1 0 / 2 5 / 1 8
More informationPalliative Care: Transforming the Care of Serious Illness
Palliative Care: Transforming the Care of Serious Illness Diane E. Meier, MD Director, Center to Advance Palliative Care diane.meier@mssm.edu www.capc.org www.getpalliativecare.org @dianeemeier No Disclosures
More informationPaul E. Stander, MD, MBA, FACP Division of Palliative Care Geriatrics and Extended Care Phoenix VAHS
Paul E. Stander, MD, MBA, FACP Division of Palliative Care Geriatrics and Extended Care Phoenix VAHS Objectives Define a population of patients with serious illness for whom improved communication holds
More informationNeuroPI Case Study: Palliative Care Counseling and Advance Care Planning
Case: An 86 year-old man presents to your office after recently being diagnosed as having mild dementia due to Alzheimer s disease, accompanied by his son who now runs the family business. At baseline
More informationHow to Develop a Comprehensive Ventricular Assist Device Program
How to Develop a Comprehensive Ventricular Assist Device Program Rodrigo V. González, MD, MS Sección de Cirugía Cardiovascular División de Cirugía Facultad de Medicina Pontificia Universidad Católica de
More information